How much weight do you lose on survodutide?

In the obesity-focused trial (Le Roux et al., Lancet Diabetes & Endocrinology, 2024), survodutide 4.8 mg produced 14.9% body weight loss at 46 weeks in adults with obesity. This is comparable to semaglutide 2.4 mg (Wegovy, approximately 15%) but below tirzepatide (20-22%). Weight loss is dose-dependent, with higher doses producing greater reductions but also more gastrointestinal side effects.

MASH Peptide Therapies

Survodutide for MASH: The Dual Agonist Liver Data

13 min read|March 25, 2026

MASH Peptide Therapies

62% MASH improvement

In the phase 2 NEJM trial, 62% of patients receiving survodutide 4.8 mg achieved MASH improvement without fibrosis worsening at 48 weeks, compared to 14% on placebo.

Sanyal et al., New England Journal of Medicine, 2024

View as image

Survodutide is a dual glucagon/GLP-1 receptor agonist developed by Boehringer Ingelheim. Unlike semaglutide and tirzepatide, which primarily target metabolic disease through appetite and insulin pathways, survodutide specifically activates the glucagon receptor alongside GLP-1. That glucagon component is why the liver data stands out: glucagon receptor activation directly drives hepatic fat oxidation, making survodutide a dual agonist with a built-in liver-targeting mechanism. For the broader landscape of peptide drugs being tested for liver disease, see the pillar article on semaglutide for liver fat.

The phase 2 trial results, published in the New England Journal of Medicine in 2024, showed survodutide produced MASH improvement rates that rival or exceed every other drug tested for this indication. The FDA granted Breakthrough Therapy designation, and two phase 3 trials are now enrolling thousands of patients.

Key Takeaways

In the 48-week phase 2 NEJM trial (n=293), 62% of patients on survodutide 4.8 mg achieved MASH improvement without fibrosis worsening, versus 14% on placebo
Liver fat reduction of at least 30% occurred in 67% of the 4.8 mg group compared to 14% on placebo
Fibrosis improvement by at least one stage occurred in 34-36% of survodutide groups versus 22% on placebo
Survodutide produced 14.9% body weight loss at 4.8 mg over 46 weeks in a separate obesity trial, comparable to semaglutide 2.4 mg
The glucagon receptor component drives direct hepatic fat oxidation, a liver-specific mechanism absent from pure GLP-1 agonists
Phase 3 trials (LIVERAGE and LIVERAGE-Cirrhosis) are enrolling approximately 3,390 patients with MASH fibrosis stages F2-F4

Why Glucagon Matters for the Liver

GLP-1 receptor agonists improve liver disease primarily through indirect mechanisms: weight loss, reduced insulin resistance, decreased inflammation. The liver itself expresses relatively few GLP-1 receptors. Glucagon receptors, by contrast, are abundantly expressed on hepatocytes.

When glucagon binds its receptor on liver cells, it activates a cascade that increases fatty acid oxidation (burning stored fat), stimulates ketogenesis, and reduces de novo lipogenesis (new fat production). This is the liver's natural fasting response, evolved to mobilize energy stores when food is scarce.

In MASH, the liver is overwhelmed with fat. Hepatocyte lipid accumulation triggers inflammation, oxidative stress, and fibrosis. A drug that directly activates the liver's fat-burning machinery, rather than waiting for systemic metabolic improvement to trickle down, has a mechanistic advantage for liver disease specifically.

Thomas and colleagues (2024) profiled survodutide's biomarker and pharmacological effects, confirming that glucagon receptor activation produces liver-specific metabolic changes distinct from those achieved through GLP-1 alone.^[1] These include increased circulating amino acids (reflecting hepatic gluconeogenesis), elevated FGF21 (a liver-derived hormone that improves metabolic health), and reduced liver enzyme levels (ALT, AST) that correlate with reduced hepatocyte injury.

The risk of glucagon agonism is hyperglycemia. Glucagon raises blood glucose by stimulating hepatic glucose output. Survodutide's dual design counterbalances this: the GLP-1 component stimulates insulin secretion and suppresses glucagon's glucose-raising effect, keeping blood sugar controlled while preserving glucagon's liver benefits.

The NEJM Phase 2 Trial: Landmark Liver Data

Sanyal and colleagues published the phase 2 results in the New England Journal of Medicine in 2024, establishing survodutide as a leading MASH candidate.^[2]

Study design: 293 adults with biopsy-confirmed MASH and fibrosis stages F1-F3 were randomized 1:1:1:1 to receive survodutide 2.4 mg, 4.8 mg, 6.0 mg, or placebo as weekly subcutaneous injections for 48 weeks. The first 24 weeks were a rapid dose-escalation phase; the final 24 weeks were maintenance.

Primary endpoint (MASH improvement without fibrosis worsening):

Survodutide 2.4 mg: 47%
Survodutide 4.8 mg: 62%
Survodutide 6.0 mg: 43%
Placebo: 14%

The 4.8 mg dose produced the strongest response. The lower response at 6.0 mg may reflect higher rates of gastrointestinal side effects leading to dose reductions or discontinuation.

Liver fat reduction (at least 30% decrease):

Survodutide 2.4 mg: 63%
Survodutide 4.8 mg: 67%
Survodutide 6.0 mg: 57%
Placebo: 14%

Fibrosis improvement (at least one stage):

Survodutide 2.4 mg: 34%
Survodutide 4.8 mg: 36%
Survodutide 6.0 mg: 34%
Placebo: 22%

The fibrosis improvement difference over placebo was smaller than the MASH improvement difference, which is typical for antifibrotic outcomes. Fibrosis takes longer to resolve than steatohepatitis, and 48 weeks may be insufficient to fully capture fibrosis regression. The phase 3 trials extend to 52 weeks for primary endpoints and 7 years for liver-related clinical outcomes.

Weight Loss Data: Competitive With Pure GLP-1 Agonists

Le Roux and colleagues (2024) published the obesity-focused trial in The Lancet Diabetes & Endocrinology.^[3] In adults with obesity (BMI 28 or higher) without diabetes:

Survodutide 4.8 mg: 14.9% body weight loss at 46 weeks
Survodutide 6.0 mg: data showed dose-dependent weight loss

For context, semaglutide 2.4 mg (Wegovy) produces approximately 15% weight loss in similar trials. Tirzepatide produces 20-22%. Survodutide's weight loss is competitive with semaglutide and below tirzepatide, but the liver-specific benefits may differentiate it for patients where MASH is the primary concern rather than obesity alone.

Wan and colleagues (2024) conducted a meta-analysis pooling survodutide weight loss data, confirming the dose-response relationship and the consistency of results across trial populations.^[4]

Diabetes Outcomes: HbA1c Reduction

Bluher and colleagues (2024) published dose-response data on HbA1c and body weight reduction in patients with type 2 diabetes.^[5] Survodutide produced clinically meaningful HbA1c reductions across dose groups, though the magnitude was not dramatically different from established GLP-1 agonists. The differentiator for survodutide is not diabetes management per se but the combination of diabetes control, weight loss, and direct liver fat reduction in a single molecule.

How Survodutide Compares to Other MASH Candidates

The MASH pipeline is crowded with peptide-based candidates. Here is how survodutide's phase 2 data compares:

Semaglutide (GLP-1 only): The phase 2 MASH trial showed 59% of patients on semaglutide 0.4 mg daily achieved MASH resolution versus 17% on placebo. Fibrosis improvement was 43% versus 33%. Semaglutide works primarily through weight loss and insulin sensitization, without direct glucagon-mediated hepatic fat oxidation.

Resmetirom (thyroid receptor agonist, not a peptide): FDA-approved in 2024 for MASH. Achieved 26-30% MASH resolution rates depending on dose. Resmetirom's mechanism is thyroid hormone receptor-beta activation in the liver, directly different from peptide-based approaches.

Retatrutide (GLP-1/GIP/glucagon triple agonist): Phase 2 data showed up to 24.2% body weight loss at 48 weeks, the highest of any metabolic peptide. Liver-specific data from retatrutide's fibrosis trial suggests even greater liver fat reduction than dual agonists, potentially due to the additional GIP receptor component.

Pemvidutide (GLP-1/glucagon dual agonist): Also targets both receptors, similar to survodutide. Pemvidutide's early data showed liver fat reductions in the range of 70-80% in imaging studies, though the patient populations and trial designs differ from survodutide's biopsy-confirmed endpoints.

Kaya and colleagues (2024) reviewed survodutide's position in the MASH landscape, arguing that its dual mechanism bridges hepatic and systemic metabolic dysfunction in a way that single-mechanism drugs cannot.^[6] For a complete mapping of every peptide being studied for MASH and the broader MASH epidemic and peptide solutions, the dedicated pipeline articles cover the full landscape.

Phase 3: LIVERAGE and LIVERAGE-Cirrhosis

Two phase 3 trials launched following the phase 2 results and FDA Breakthrough designation:

LIVERAGE enrolls approximately 1,800 adults with biopsy-confirmed MASH and fibrosis stages F2 or F3 (moderate to advanced fibrosis, not yet cirrhosis). Part 1 runs 52 weeks with co-primary endpoints: MASH resolution without fibrosis worsening, and fibrosis improvement without MASH worsening. Part 2 continues for approximately 7 years, measuring time to first liver-related clinical event or all-cause mortality.

LIVERAGE-Cirrhosis enrolls approximately 1,590 adults with compensated MASH cirrhosis (fibrosis stage F4). This is a higher-risk population that no peptide-based therapy has successfully treated in a pivotal trial.

Both trials use histological endpoints (liver biopsies at baseline and week 52) rather than imaging-based liver fat measurement, which is a higher bar for demonstrating efficacy but provides more clinically meaningful data. The biopsy requirement limits enrollment (many patients decline repeated liver biopsies) but strengthens the regulatory case for approval.

The combined enrollment of approximately 3,390 patients makes this one of the largest clinical trial programs in liver disease. The 7-year follow-up in Part 2 is designed to answer whether histological improvement translates to reduced liver-related mortality, liver transplant, hepatocellular carcinoma, and decompensation events.

Safety Profile: What Phase 2 Showed

The most common adverse events were gastrointestinal: nausea, diarrhea, vomiting, and decreased appetite. These are expected class effects of GLP-1 receptor agonism and were consistent with other drugs in this class.

Lawitz and colleagues (2024) published detailed efficacy, tolerability, and pharmacokinetics data from an earlier trial, confirming the dose-dependent relationship between survodutide exposure and both efficacy and gastrointestinal side effects.^[7]

The glucagon component raises a theoretical concern about hyperglycemia, particularly in diabetic patients. In practice, the GLP-1 component adequately counterbalances this: blood glucose levels did not increase, and HbA1c actually improved across dose groups in diabetic patients. However, this balance could be disrupted in patients with severe insulin resistance or advanced diabetes. The phase 3 trials will provide the largest safety dataset for this drug-class interaction, particularly in cirrhotic patients (LIVERAGE-Cirrhosis) whose hepatic glucose metabolism is already compromised.

Dutta and colleagues (2025) conducted a systematic review of survodutide's efficacy and safety on glycemic control, confirming that the dual agonist maintains glucose homeostasis while achieving its metabolic and hepatic benefits.^[8]

The Cardiometabolic Connection

Arun and colleagues (2025) reviewed survodutide as a "reshaping" agent for cardiometabolic care, arguing that its effects extend beyond liver and weight to cardiovascular risk factors.^[9] Patients with MASH have dramatically elevated cardiovascular risk; the leading cause of death in MASH patients is cardiovascular disease, not liver failure. A drug that simultaneously reduces liver fat, body weight, blood glucose, and cardiovascular risk factors addresses the full disease burden rather than a single organ system.

Whether the phase 3 LIVERAGE trials will include cardiovascular outcome measures as secondary endpoints has not been publicly confirmed, but the overlap between MASH and cardiovascular disease makes this a likely consideration for regulatory discussions.

Chrysavgis and colleagues (2025) positioned GLP-1 receptor agonists broadly as "pan-steatotic liver disease" treatments, noting their effects across the spectrum from simple steatosis to MASH to cirrhosis.^[10] Survodutide's glucagon component may provide additional benefit at the MASH end of this spectrum, where active hepatic fat oxidation is most needed.

The Bottom Line

Survodutide's phase 2 NEJM data showed MASH improvement rates of 62% at the optimal dose, liver fat reduction in 67% of patients, and fibrosis improvement in 36%, all significantly exceeding placebo. The dual GLP-1/glucagon mechanism provides a liver-specific advantage through direct hepatic fat oxidation that pure GLP-1 agonists lack. Phase 3 trials enrolling 3,390 patients are underway, with liver-related mortality as a long-term endpoint. The drug's position in the MASH pipeline depends on whether its glucagon-driven liver specificity translates to superior fibrosis outcomes over 7 years.

Frequently Asked Questions

Survodutide is a dual glucagon/GLP-1 receptor agonist developed by Boehringer Ingelheim, given as a weekly subcutaneous injection. It activates both the glucagon receptor (which drives fat burning in the liver) and the GLP-1 receptor (which controls appetite and insulin secretion). This dual mechanism directly targets liver fat through glucagon-mediated hepatic fat oxidation while controlling blood sugar and body weight through GLP-1 effects.

The phase 2 trial (Sanyal et al., NEJM, 2024) randomized 293 adults with biopsy-confirmed MASH and fibrosis (F1-F3) to survodutide or placebo for 48 weeks. At the 4.8 mg dose, 62% achieved MASH improvement without fibrosis worsening (vs. 14% placebo), 67% had at least 30% liver fat reduction (vs. 14%), and 36% improved fibrosis by at least one stage (vs. 22%). The FDA granted Breakthrough Therapy designation based on these results.

Survodutide's MASH improvement rate of 62% at 4.8 mg is comparable to semaglutide's 59% in its own phase 2 MASH trial. The key mechanistic difference is survodutide's glucagon receptor activation, which directly increases hepatic fat oxidation. Semaglutide improves liver disease primarily through weight loss and insulin sensitization. Whether survodutide's direct liver mechanism translates to better long-term fibrosis and mortality outcomes will be determined by the ongoing phase 3 trials.

No, survodutide is not yet FDA approved for any indication as of 2026. It received FDA Breakthrough Therapy designation for MASH in 2024 based on phase 2 results. Two phase 3 trials (LIVERAGE and LIVERAGE-Cirrhosis) are currently enrolling patients, with primary endpoint data expected after 52 weeks of treatment. If successful, FDA approval could follow, but the timeline depends on trial completion and regulatory review.

The most common side effects in clinical trials were gastrointestinal: nausea, diarrhea, vomiting, and decreased appetite. These are expected effects of GLP-1 receptor agonism and were generally manageable. Despite including a glucagon component (which can raise blood sugar), survodutide did not cause hyperglycemia in trials because the GLP-1 component counterbalances the glucagon effect on glucose. The 4.8 mg dose showed better tolerability than 6.0 mg.